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Vision-related quality of life and 
symptom perception change over 
time in newly-diagnosed primary 
open angle glaucoma patients
Ivano Riva  1, Lorenzo Legramandi2, eliana Rulli  2, Anastasios G. Konstas3, 
Andreas Katsanos4, Francesco oddone1, Robert N. Weinreb5, Luciano Quaranta6 &  
the Italian study Group on QoL in Glaucoma*
to evaluate the change over time of vision-related quality of life (QoL) and glaucoma symptoms 
in a population of newly-diagnosed primary open angle glaucoma (poAG) patients. Multicenter, 
prospective study. Consecutive newly-diagnosed poAG patients were enrolled and followed-up for one 
year. Follow-up visits were scheduled at 6 and 12 months from baseline. At each visit, vision-related 
QoL and glaucoma-related symptoms were assessed by the means of the 25-item National Eye Institute 
Visual Function Questionnaire (NEI-VFQ-25) and the Glaucoma Symptom Scale (GSS), respectively. 
Trends over time for NEI-VFQ-25 and GSS scores were evaluated with longitudinal linear mixed models. 
one-hundred seventy-eight patients were included in the analysis. At baseline, early to moderate 
glaucoma stages were associated with higher scores for most GSS and NEI-VFQ-25 items, while lower 
best-corrected visual acuity was associated with lower scores for 4 of the 12 NEI-VFQ-25 items. During 
the follow-up, all the GSS scores, the NEI-VFQ-25 total score, and 7 of the 12 NEI-VFQ-25 scores 
significantly improved (p < 0.05). In multivariate model, higher increases of most GSS and NEI-VFQ-25 
scores were modeled in patients with low scores at baseline. Vision-related QoL and glaucoma-related 
symptom perception significantly improved during the one-year follow-up in this population of newly 
diagnosed poAG patients.
Glaucoma, one of the leading causes of blindness in the world1, is characterized by progressive visual field (VF) 
deterioration and optic disc damage2. Primary open angle glaucoma (POAG), the most common type of glau-
coma in white populations3, has a chronic course with functional impairment developing over years. Although 
glaucoma is an irreversible disease, its progression may be delayed with appropriate medical and surgical 
management4–6.
In recent years, quality of life (QoL) has assumed a leading role in health-care, and its preservation is now one 
of the main goals of treatment7,8. As a chronic disease, POAG may affect QoL9–14. VF loss and central visual acuity 
impairment may limit daily activities, such as reading15,16, walking17 or driving18,19. Additionally, topical medica-
tions20,21, surgical interventions22,23 and the need for long-term care are additional factors that can significantly 
affect QoL.
Several studies have evaluated QoL in glaucoma and the association with its clinical aspects, such as VF 
damage (VFD)9,10,24,25 and best corrected visual acuity (BCVA) deterioration24,26, or the presence of unilateral 
versus bilateral disease27,28. A significant correlation between disease severity and the impairment of QoL has 
been found using either generic or vision-specific instruments14. However, the majority of these studies had a 
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cross-sectional design, whereby data collected at a single time-point were analyzed. Differently, the Collaborative 
Initial Glaucoma Treatment Study (CIGTS) prospectively evaluated QoL changes in newly-diagnosed glaucoma 
patients, randomized to medical or surgical treatment, over a 5-year follow-up23. As a result, the overall trend was 
a decline in the percent of participants of both groups reporting the presence of functional and local symptoms 
over time, suggesting an improvement of patient’s QoL perception. However, the CIGTS used a proprietary mul-
tidimensional instrument developed by the CIGTS investigators, and interviews were performed by phone. No 
other study subsequently applied the same QoL instrument.
The Italian Primary Open Angle Glaucoma Study (IPOAGS) is a multicenter study designed to evaluate 
vision-related QoL in Italian POAG patients29–31. The IPOAGS consists of a cross-sectional and a prospective part. 
The present report describes the results of the prospective part, the aim of which was to assess possible changes in 
vision-related QoL and symptom perception over time, and to identify patterns of QoL modification according 
to the characteristics of the disease.
Material and Methods
The design and methods of the IPOAGS have been described elsewhere29–31. Briefly, previously or newly diag-
nosed POAG patients aged 18 or more were consecutively enrolled during routine visits at 21 academic and 
non-academic centers in Italy. In the cross-sectional part of the study, vision-related QoL data were collected and 
their association with both clinical and socio-demographic variables was investigated29,30. In the prospective part 
of the study, consecutive newly-diagnosed glaucoma patients were evaluated at baseline and were followed-up 
for one year.
Informed consent was obtained from all the participants before any study-related procedure and after the 
nature and the purpose of the investigation were fully explained. The study was conducted in accordance with 
the tenets of the Declaration of Helsinki and the Guidelines for Good Clinical Practice. The Institutional Review 
Board of Brescia (Brescia, Italy) and of each participating center approved the protocol. The study was registered 
at clinicaltrials.gov (NCT01742104).
Interventions. Newly-diagnosed POAG patients underwent a comprehensive ophthalmological examination 
at baseline and at each follow-up visit. Follow-up study visits were scheduled at 6 and 12 months from baseline, 
however interim visits were allowed at clinician discretion, to adjust therapy and evaluate target IOP. Treatment 
was initiated, at the end of the baseline visit, to avoid an influence of drugs and interventions on QoL assessment. 
At baseline and at 6- and 12-month follow-up visits, VF examination was performed and vision-related QoL and 
glaucoma symptom perception questionnaires were administered.
POAG was defined as a typical optic neuropathy with a focal, generalized or focal/generalized neuroretinal 
thinning or an inter-eye cup/disc ratio asymmetry >0.2. The presence of typical glaucomatous VF defects was not 
a prerequisite for inclusion, if the investigator’s clinical judgment was strongly in favor of POAG (e.g. due to high 
intraocular pressure (IOP), retinal nerve fiber layer defects or optic disc hemorrhages)32.
Vision-related QoL was assessed using the validated Italian version of the 25-item National Eye Institute 
Visual Function Questionnaire (NEI-VFQ-25)33, while glaucoma-related symptoms were assessed using the val-
idated Italian version of the Glaucoma Symptom Scale questionnaire (GSS)34.
The NEI-VFQ-25 is a self-administered questionnaire, developed to investigate vision-related QoL35. It con-
sists of 25 vision-targeted questions, representing 11 vision-related constructs (general vision, ocular pain, near 
activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision 
and peripheral vision), plus an additional single-item question for general health rating. The scoring procedure 
converts the pre-coded numeric values of each item to a score ranging from 0 to 100. Higher scores reflect better 
vision-related QoL. The total score is the mean of all the vision-targeted subscales scores.
The GSS is a glaucoma-specific tool designed for the investigation of symptoms in patients with glaucoma36. 
It was developed as a modified instrument from a checklist of symptoms applied in the Ocular Hypertension 
Treatment Study36. It includes 10 items grouped in two domains: Symp-6 for non-visual symptoms (burning/
smarting/stinging, tearing, dryness, itching, soreness/tiredness, feeling of something in the eye) and Func-4 for 
visual symptoms (blurry/dim vision, hard to see in daylight, hard to see in darkness, and halos around the lights). 
Each item can take a score from 0 to 100, where 0 indicates very bothersome symptoms and 100 the absence of 
symptoms. The domain score is the mean from the items of the relative domain, while the total GSS score is the 
mean from all items of both domains. Each eye is tested separately.
Visual field and stage of the disease. A reliable VF examination at baseline (i.e. false-positive responses 
<15% with a clear blind-spot at the VF printout, threshold value <10 dB) was required for study inclusion. 
Severity of VF impairment was classified at baseline and at each follow-up visit according to the Glaucoma 
Staging System 2 (GStag2)37,38. GStag2 is a classification method using Mean Deviation (MD) or Mean Defect and 
Pattern Standard Deviation/Corrected Pattern Standard Deviation (PSD/CPSD) and Loss Variation/Corrected 
Loss Variation (LV/CLV) values (from either the 30-2/24-2 Zeiss-Humphrey tests or the G1/G1X/G2 Octopus 
programs) to create a Cartesian coordinate diagram. VF is classified into seven different stages by curvilinear lines 
from stage 0 (normal VF) to stage 5 (low threshold readings, with only small remnants of sensitivity). GStag2 has 
been validated in population-based studies39–43 and has been shown to be similar or superior to other VF clas-
sification systems44. The improvement of performance in perimetric tests is a well-known phenomenon, called 
“learning effect”. To prevent bias, the “worst value carry backward” method was used: for each eye, the highest 
value of glaucoma stage during the follow-up replaced the earlier values.
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statistical analysis. All the tests were performed considering patient as unit of analysis. In patients with 
bilateral disease, arithmetical means of BCVA and MD were computed, while the lowest GSS score and the worst 
stage of the disease were chosen.
For statistical purposes, stage of the disease was categorized as follows: early (stage 0, borderline and 1), mod-
erate (stage 2 and 3) and severe (stage 4 and 5). BCVA was dichotomized as ≤ or >0.15 LogMar. Since the 
information on prescribed treatments were collected at fixed time-points (baseline, 6 and 12-month visits), but 
treatment variation was at clinician’s discretion during the follow-up, data from 6-month visit were taken as a 
representative proxy of the entire follow-up.
Vision-related QoL and symptom scores expressed as a mean of different subscale scores (e.g. total 
NEI-VFQ-25 or total GSS scores) were treated as continuous variables. Single-item scores and scores with a 
value of 100 for more than 50% of the interviewed subjects were treated as dichotomous variables. In this case, 
“1” was assigned to the maximum score of 100, and “0” to other values. Dichotomized variables, exclusively for 
the NEI-VFQ-25 were: distance activities, color vision, peripheral vision, social functioning, role difficulties and 
dependency.
NEI-VFQ-25 and GSS scores at baseline were investigated by the means of multivariable general linear models 
and logistic models. Vision-related QoL and symptom scores over time were modeled as a linear function of time. 
A multivariable analysis including time, baseline QoL scores and their interaction with time and covariates was 
performed. The adjustment for baseline QoL scores and interaction with time was performed taking into account 
regression toward the mean and ceiling effect. Longitudinal linear mixed models and generalized longitudinal 
mixed models for binary data with a marginal logit link function (modeled the probability of score = “100”) 
were used for the analyses of dichotomized scores. The effect of time was modeled as a linear function. Random 
intercepts and random slopes for time effect were introduced to interpolate the subject-specific deviations from 
the score trends.
A significance level of p < 0.05 was set. All the analyses were performed with SAS software (version 9.4).
Results
From March 2012 to July 2013, one hundred ninety-seven newly-diagnosed POAG patients were enrolled. 
Nineteen patients were then excluded from the analysis, 11 because they did not have follow-up data and 8 
because they did not have data on anti-glaucoma prescriptions. Therefore, analyses were performed on 178 
subjects.
Demographic characteristics of the study participants are presented in Table 1. Mean age was 61.7 years (SD 
14.3), and 52.8% of the participants were females. Mean values for MD and BCVA were −4.5 dB (SD 5.3) and 
0.1 LogMar (SD 0.1). According to the GStag2, disease severity was classified as early (stage 0, borderline ad 1) 
in 95 patients (53.3%), moderate (stage 2 and 3) in 56 patients (31.5%) and severe (stage 4 and 5) in 27 patients 
(15.2%). After the baseline visit, all the patients were administered one or more hypotensive topical medications 
(Table 2). Eighty-nine patients (50%) were administered a prostaglandin analogue alone, while a β-blocker was 
administered in 53 patients (29.8%). Thirty patients (16.8%) received more than one topical agent as a first-line 
therapy. During the follow-up, 8 patients (4.4%) underwent surgery and 27 patients received laser treatment (i.e. 
selective laser trabeculoplasty, 15.2%), in addition to medical therapy.
Vision-related QoL scores at baseline. Results of multivariable analyses on baseline QoL scores are 
showed in Table 3. Being a man (p = 0.03) and having an early/moderate vs. severe stage of the disease (p < 0.01) 
were variables associated with higher values of GSS Func-4 score at baseline. Early or moderate vs. severe stages of 
the disease were associated with higher values of most NEI-VFQ-25 scores, with the exception of general health 
(p = 0.06) and ocular pain (p = 0.11). BCVA was significantly related to total NEI-VFQ-25 score and to 3 of the 
12 NEI-VFQ-25 subscale scores (near activities: p = 0.01, role difficulties: p < 0.01 and driving: p < 0.01). Being a 
man was associated with higher NEI-VFQ-25 driving score (p < 0.01).
Overall N = 178
Age–Mean (SD) 61.7 (14.3)
Male sex–n (%) 84 (47.2)
Visual field MD (dB) - Mean (SD) −4.5 (5.3)
BCVA (LogMar)–Mean (SD) 0.1 (0.1)
Stage of the disease*–n (%)
  Stage 0 2 (1.1)
  Border 47 (26.4)
  Stage 1 46 (25.8)
  Stage 2 35 (19.7)
  Stage 3 21 (11.8)
  Stage 4 10 (5.6)
  Stage 5 17 (9.6)
Table 1. Demographic and clinical characteristics of study participants at baseline. Legend: N: total number of 
participants; SD: Standard Deviation; MD: Mean Deviation; dB: Decibel BCVA: Best Corrected Visual Acuity. 
*According to Glaucoma Staging System 2.
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Vision-related QoL and symptom score change over time. GSS and NEI-VFQ-25 scores at baseline 
and at all follow-up visits are presented in Table 4. Mean baseline scores were higher than 75 in all the subscales, 
with the exception of NEI-VFQ-25 general health (60.4, SD 17.0), and NEI-VFQ-25 general vision (65.8, SD 
15.4) scores. Color vision had the highest score (94.2, SD 8.0), followed by social functioning (97.7, SD 6.9) and 
dependency (95.5, SD 12.6). NEI-VFQ-25 and GSS total scores were 88.3 (SD 11.3) and 78.1 (SD 18.0), respec-
tively. Over the 1-year follow-up, both the NEI-VFQ-25 and the GSS scores increased. The increase of all the GSS 
scores, the NEI-VFQ-25 total score and 7 of the 12 NEI-VFQ-25 subscale scores (general health, general vision, 
ocular pain, near activities, mental health, role difficulties and driving) was significant. Trends over time for the 
GSS and the NEI-VFQ-25 total scores and for the main subscale scores are presented in Fig. 1.
Results of multivariable analyses on NEI-VFQ-25 and GSS scores over time are reported in Table 5. A signifi-
cant negative interaction was observed between time and all the GSS scores, the NEI-VFQ-25 total score and 8 of 
the 12 NEI-VFQ-25 subscale scores at baseline (general health, general vision, ocular pain, near activities, social 
functioning, mental health, role difficulties and dependency). As a result, a lower baseline score was related to a 
higher increase of the score during the follow-up (Fig. 2). A negative interaction between time and baseline stage 
of the disease was found for GSS Func-4 score (p < 0.01) and NEI-VFQ-25 ocular pain score (p = 0.02) (Fig. 3). In 
thise case, lower glaucoma stages at baseline (i.e. early or moderate disease) were associated with higher increase 
of QoL score over time. With regard to NEI-VFQ-25 dichotomized scores, a significant interaction between stage 
of the disease and time was detected on vision-specific role difficulties (p = 0.01, Fig. 4A) and peripheral vision 
(p = 0.016, Fig. 4B, available online) scores. This means that patients without a maximum score (<100) and 
with an early to moderate disease at baseline, had a high probability to achieve the maximum score during the 
follow-up. Patients with a maximum QoL score (100) at baseline and a severe disease, more easily experienced a 
QoL score reduction over time.
Discussion
Several cross-sectional studies have found a significant association between VF and BCVA deterioration and 
vision-related QoL in glaucoma patients”. However, only a few studies investigated QoL with a prospective 
design23,24. The present study aimed to evaluate vision-related QoL and glaucoma-related symptom perception 
both at baseline and prospectively, in a group of newly-diagnosed glaucoma patients followed-up for one year. As 
a result, GSS and NEI-VFQ-25 scores were generally high at baseline (i.e. >75), indicating that this population of 
newly-diagnosed glaucoma patients perceived a high level of QoL. Stage of the disease and BCVA were the most 
important determinants of QoL at baseline. As GStag2 resides entirely on VFD, these findings are not surprising 
and are in agreement with previous cross-sectional studies, where a significant correlation between both VF 
and BCVA with QoL was found9,10,23. In a recent study analyzing QoL of patients enrolled in the Early Manifest 
Glaucoma Trial and followed-up for 20 years, visual acuity and VF index were the only significant variables 
influencing QoL, accounting for nearly 40% of NEI-VFQ-25 scores9. On the other hand, both visual acuity and 
VF scores were weakly but significantly associated with QoL measures in newly-diagnosed glaucoma patients 
enrolled in the CIGTS10. Beside these data, it is unknown if QoL in glaucoma is more affected by VFD or BCVA 
deterioration. In the present study, stage of the disease was associated with 2 of the 3 GSS scores at baseline, and 
with all the NEI-VFQ-25 scores, with the exception of general health and ocular pain. BCVA was associated 
with only 3 of the 12 NEI-VFQ-25 scores and with total NEI-VFQ-25 score. These results probably suggest a 
Overall N = 178
Intervention – n (%)
Topical, surgical and laser 4 (2.2)
Topical and Surgical 4 (2.2)
Topical and Laser 27 (15.2)
Only Topical 143 (80.3)
Topical Treatments – n (%) Baseline 6 months 12 months
β-blockers 54 (30.3) 46 (25.8) 47 (26.4)
Carbonic anhydrase inhibitors 7 (3.9) 7 (3.9) 12 (6.7)
Prostaglandin analogues 96 (53.9) 108 (60.7) 100 (56.2)
Parasympathomimetics 0 (0.0) 1 (0.6) 1 (0.6)
Prostaglandin + beta-blocker FC 15 (8.4) 16 (9.0) 26 (14.6)
Alpha agonist + beta-blocker FC 1 (0.6) 1 (0.6) 1 (0.6)
Carbonic anhydrase inhibitor + β-blocker FC 12 (6.7) 18 (10.1) 15 (8.4)
Other 2 (1.1) 2 (1.1) 2 (1.1)
Number of active agents – n (%) Baseline 6 months 12 months P-valuea
0 0 (0.0) 1 (0.6) 5 (2.8) <0.01
1 148 (83.1) 133 (74.7) 120 (67.9)
2 23 (12.9) 31 (17.4) 35 (19.7)
≥3 7 (3.9) 13 (7.3) 18 (10.1)
Table 2. Treatments of patients included in the study. Legend: N: Total number of participants; FC: Fixed 
combination; aFriedman test.
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prominent role of VFD as a determinant of QoL in newly-diagnosed glaucoma patients, albeit further researches 
are needed to confirm these findings.
Men showed a higher perception of their visual function at baseline (GSS Func-4 score), and were more con-
fident at driving than women (NEI-VFQ-25 driving score). Sex-related psychological profiles are likely involved 
in these results. Previous studies have found women to be more prone to reporting symptoms than men45,46 and 
to engage more easily in illness behaviors46. Nevertheless, anxiety and depression, two common responses to the 
diagnosis of a chronic illness47 are more common in women than men48–50. Our results about driving are in agree-
ment with the conclusions of previous studies, where women with glaucoma were more likely to cease driving 
than men18,51.
In our study NEI-VFQ-25 total score and most of the NEI-VFQ-25 subscale scores significantly increased 
from baseline to the 1-year follow-up visit, which suggests a general pattern of improvement in vision-related 
QoL. Similarly, the GSS total score as well as symptom and function subscale scores improved, which suggests a 
blunting of glaucoma-related symptom perception over time. Reason of this change is unknown, however adap-
tation to glaucoma diagnosis may be involved. Adaptation to a chronic illness is a well-known phenomenon 
in general medicine, and has been extensively investigated52–55. Several reports from different disciplines have 
highlighted the role of adaptation to the diagnosis and its impact on QoL of various chronic diseases and disa-
bilities56–58. Adaptation theories have been also translated into clinically meaningful rehabilitation programs57. 
Little is known about the effects of adaptation to the diagnosis of glaucoma, and a few studies have investigated 
this phenomenon. Interestingly, in many participants of the CIGTS, the diagnosis of glaucoma engendered an 
immediate response of fear of blindness59. However, the percentage of respondents who reported moderate or sig-
nificant apprehension dropped from 34% at baseline to less than 15% after 12 months. In the same study, a slight 
but significant decline in symptom scale scores was recorded during the follow-up, indicating an improvement 
in the perception of glaucoma-related symptoms23. Psychological adaptation to the diagnosis of glaucoma was 
offered as an explanation of these results, while less convincing was the hypothesis of a diminution or cessation 
of the particular problem.
Two variables greatly influenced QoL score change over time in our study: QoL score at baseline and stage 
of the disease. While the interaction of time with baseline QoL scores was significant over most GSS and 
NEI-VFQ-25 scores, the interaction of baseline stage with time was significant only for GSS Function-4 score and 
NEI-VFQ-25 ocular pain, role difficulties and peripheral vision scores. According with this analysis, higher QoL 
score increase over time was modeled in patients with lower QoL score at baseline and less advanced disease. Both 
psychological and clinical factors are likely to be involved in these results. Psychological impact of the diagnosis of 
a chronic illness is quite different according to personality traits and life expectation60,61. The process of adaptation 
may mitigate the initial response over time, and a greater increase in QoL scores may be expected in patients that 
N = 151
Age (for 10-year increase) Sex (ref. female) Baseline stagea
Baseline BCVA (≤0.15 vs 
>0.15 LogMar)
Slope/OR [95% CI]
P-value 
F-test Slope/OR [95% CI]
P-value 
F-test
Early vs Severe Moderate vs Severe P-value 
F-test Slope/OR [95% CI]
P-value 
F-testSlope/OR [95% CI] Slope/OR [95% CI]
Glaucoma Symptom Scale (GSS)b
Symp-6 1.01 [−1.30; 3.32] 0.39 4.01 [−2.33;10.36] 0.21 8.99 [−0.16;18.14] 10.43 [0.84;20.02] 0.09 6.31 [−2.80;15.41] 0.17
Func-4 0.11 [−2.12; 2.34] 0.93 7.00 [0.86;13.13] 0.03 20.77 [11.93;29.62] 20.51 [11.24;29.78] <0.01 8.02 [−0.78;16.82] 0.07
Total score 0.60 [−1.32; 2.53] 0.54 5.11 [−0.19;10.40] 0.06 14.05 [6.41;21.68] 14.94 [6.93;22.94] <0.01 7.43 [−0.17;15.03] 0.06
National Eye Institute Visual Function Questionnaire (NEI-VFQ-25)b
General health −1.44 [−3.44; 0.56] 0.16 1.49 [−4.02; 7.00] 0.59 9.25 [1.30;17.19] 5.09 [−3.24;13.42] 0.06 1.11 [−6.79; 9.02] 0.78
General vision −1.42 [−2.99; 0.15] 0.08 −2.26 [−6.57; 2.05] 0.30 18.08 [11.86;24.29] 13.94 [7.42;20.45] <0.01 3.09 [−3.10; 9.27] 0.33
Ocular pain 1.15 [−1.13; 3.43] 0.32 −0.04 [−6.30; 6.23] 0.99 7.08 [−1.95;16.11] 10.13 [0.67;19.60] 0.11 6.89 [−2.09;15.88] 0.13
Near activities 0.30 [−1.50; 2.10] 0.74 1.94 [−3.00; 6.89] 0.44 16.72 [9.59;23.86] 16.18 [8.70;23.66] <0.01 10.07 [2.97;17.17] 0.01
Distance activitiesc 0.85 [0.65; 1.11] 0.22 1.49 [0.73; 3.06] 0.27 19.37 [4.04;92.86] 19.18 [3.81;96.41] <0.01 1.85 [0.64; 5.31] 0.25
Social functionigc 1.09 [0.75; 1.59] 0.65 2.87 [0.93; 8.92] 0.07 15.11 [4.04;56.51] 10.94 [2.87;41.69] <0.01 2.02 [0.54; 7.63] 0.30
Mental health 0.82 [−1.03; 2.66] 0.39 1.26 [−3.82; 6.33] 0.63 23.21 [15.89;30.53] 18.77 [11.10;26.44] <0.01 3.79 [−3.50;11.07] 0.31
Role difficultiesc 1.14 [0.87; 1.50] 0.34 1.42 [0.66; 3.05] 0.37 4.13 [1.49;11.44] 4.58 [1.52;13.79] 0.01 4.65 [1.65;13.08] <0.01
Dependencyc 0.85 [0.59; 1.22] 0.38 1.02 [0.40; 2.57] 0.97 19.90 [5.61;70.57] 7.00 [2.23;22.02] <0.01 2.46 [0.81; 7.51] 0.11
Drivingd −1.09 [−2.96; 0.78] 0.25 10.63 [5.54;15.72] <0.01 11.52 [4.39;18.65] 8.95 [1.29;16.61] 0.01 14.09 [6.43;21.76] <0.01
Color visionc 0.97 [0.56; 1.69] 0.92 4.03 [0.82;19.82] 0.09 36.68 [3.77;357.3] 13.50 [2.22;82.17] <0.01 1.52 [0.27; 8.60] 0.63
Peripheral visionc 0.81 [0.59; 1.12] 0.21 1.83 [0.77; 4.35] 0.17 9.85 [3.25;29.89] 8.84 [2.75;28.40] <0.01 1.61 [0.54; 4.84] 0.39
Total score 0.01 [−1.08; 1.10] 0.98 1.77 [−1.24; 4.77] 0.25 14.88 [10.55;19.21] 13.63 [9.09;18.17] <0.01 5.93 [1.62;10.24] 0.01
Table 3. Analysis of Glaucoma Symptom Scale (GSS) and 25-item National Eye Institute Visual Function 
Questionnaire (NEI-VFQ-25) scores at baseline by covariates (multivariable model). Legend: N: Number of 
participants; BCVA: Best Correct Visual Acuity; OR: Odds Ratio; CI: Confidence Interval; aStage = Early (0/
borderline/1); Moderate (2/3); Severe (4/5) bLinear or logistic regression models (modeled the probability 
of score = “100”); cDichotomous score (‘ = 100’, ‘<100’). dData available for 111 patients; Bold and italic: 
Significant cvalues.
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initially negatively reacted to the diagnosis. While psychological factors may be alleviated over time, functional 
factors persist, and their effect on QoL is likely to be permanent. As a consequence, patients with severe disease 
at baseline had a trend towards a stabilization or a reduction of their QoL scores over time, irrespectively of score 
values at baseline.
All the patients included in this study were administered topical hypotensive medications after the baseline 
visit. Moreover, 27 patients underwent laser treatment and 8 patients underwent surgery during the follow-up. 
Glaucoma medications may affect QoL, due to the local side effects (burning, stinging, blurred vision, etc.), and 
the bothersomeness of time-fixed administrations, potentially interfering with daily routine62,63. In our study a 
trend towards an increase in the number of topical agents per patient was found over time. This is not surprising, 
as it’s common practice to initiate glaucoma therapy with a single agent and add further medications if target IOP 
is not achieved. Despite the raise in medication number, QoL scores increased over the follow-up, including the 
Score
Baseline N = 178 
Mean (SD)
6-month N = 178 
Mean (SD)
12-month N = 178 
Mean (SD)
Mixed modelsa
Slopes/OR (for 
6-month increase) [CI] P-value
Glaucoma Symptoms Scale
Symp-6 76.2 (21.1) 77.0 (19.6) 79.8 (19.9) 1.81 [0.55; 3.08] <0.01*
Func-4 81.2 (20.1) 81.3 (20.8) 85.8 (18.2) 2.32 [0.99; 3.64] <0.01*
Total Score 78.1 (18.0) 78.7 (17.6) 82.2 (17.5) 2.06 [1.03; 3.10] <0.01*
National Eye Institute Visual Function Questionnaire (NEI-VFQ-25)
General health 60.4 (17.0) 62.3 (17.9) 64.6 (19.4) 2.13 [0.99; 3.28] <0.01*
General vision 65.8 (15.4) 67.4 (15.0) 69.8 (15.7) 2.01 [0.89; 3.13] <0.01*
Ocular pain 79.5 (19.9) 81.3 (17.6) 83.3 (18.5) 1.90 [0.57; 3.22] <0.01*
Near activities 86.2 (17.4) 87.8 (15.8) 89.8 (14.7) 1.80 [0.69; 2.91] <0.01*
Distance activitiesb–n (%) (100) 92 (51.7) 93 (52.3) 98 (55.1) 1.24 [0.80; 1.91] 0.33
Social functioningb–n (%) (100) 155 (87.1) 147 (82.6) 154 (86.5) 0.96 [0.63; 1.45] 0.83
Mental health 83.8 (18.2) 82.7 (18.8) 86.0 (17.4) 1.14 [0.15; 2.14] 0.03*
Role difficultiesb–n (%) (100) 123 (69.1) 121 (68.0) 137 (77.0) 1.80 [1.06; 3.06] 0.03*
Dependencyb – n (%) (100) 144 (80.9) 142 (79.8) 152 (85.4) 1.58 [0.85; 2.94] 0.15
Drivingc 87.8 (16.4) 88.5 (16.2) 90.6 (14.8) 0.99 [0.03; 1.94] 0.04*
Color visionb–n (%) (100) 168 (94.4) 166 (93.3) 163 (91.6) 0.93 [0.29; 2.94] 0.90
Peripheral visionb–n (%) (100) 140 (78.7) 130 (73.0) 139 (78.1) 1.32 [0.71; 2.48] 0.38
Total Score 88.3 (11.3) 88.6 (10.7) 90.0 (11.2) 0.87 [0.32; 1.41] <0.01*
Table 4. Glaucoma Symptom Scale (GSS) and 25-item National Eye Institute Visual Function Questionnaire 
(NEI-VFQ-25) scores by visit. Legend: N: Number of participants; OR: Odds Ratio; CI: Confidence Interval; 
aLongitudinal linear mixed model or logistic longitudinal mixed model (modeled the probability of 
score = “100”); bDichotomous score (‘ = 100’, ‘<100’); cData available for 145 patients. *Significant values.
Figure 1. Trends over time of Glaucoma Symptom Scale (GSS) and 25-item National Eye Institute Visual 
Function Questionnaire (NEI-VFQ-25) scores. (A) Trends over time of GSS total score, Function-4 and 
Symptoms-6 subscale scores; (B) Trends over time of NEI-VFQ-25 total score, general health and general vision 
subscale scores.
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GSS Symp-6 score, that specifically evaluates local symptoms (burning/smarting/stinging, tearing, dryness, itch-
ing, soreness/tiredness, feeling of something in the eye). Moreover, when patients were dichotomized according 
to the number of topical treatments received (one vs. more than one), no significant interaction with time was 
found. These results are somehow unexpected. However, it is possible that the mechanism of adaptation may be 
valid not only for the psychological burden of a new diagnosis, but also for the symptoms of the disease and its 
treatment23.
Our study has a number of limitations. First, no rigorous methodology for VF progression evaluation was 
adopted, as the follow-up was considered too short for a such analysis. However, taking into account the mild 
VFD at baseline (mean MD: −4.5 ± 5.3), it is unlikely that VF changes had an effect on QoL, with the obvious 
exception of patients with very fast progression and very high IOP. Second, data from both eyes were included 
in the analysis, when available. It is debated if vision-related QoL in glaucoma patients is more dependent on the 
patients’ better eye, worse eye or a combination thereof9,17,27,64. The decision to include data from both eyes of 
participants with bilateral disease was made in an attempt to obtain a model that reflects the real-life perception of 
N = 150
P-value
Baseline QoL score*time
P-value 
Sex*time
P-value 
Age*time
P-value 
aStage*time
P-value 
BCVA*time
P-value 
Treat*time
Glaucoma Symptom Scale (GSS)
Symp-6 <0.001 0.673 0.594 0.113 0.950 0.619
Func-4 <0.001 0.256 0.759 0.009 0.333 0.940
GSS score <0.001 0.561 0.855 0.108 0.984 0.921
National Eye Institute Visual Function Questionnaire (NEI-VFQ-25)
General health 0.001 0.345 0.248 0.759 0.186 0.239
General vision <0.001 0.057 0.192 0.908 0.147 0.528
Ocular pain <0.001 0.176 0.321 0.027 0.321 0.768
Near activities <0.001 0.434 0.295 0.495 0.329 0.526
Distance activitiesb 0.764 0.068 0.508 0.248 0.843 0.076
Social functioningb <0.001 0.907 0.690 0.172 0.760 0.054
Mental health <0.001 0.262 0.643 0.269 0.701 0.203
Role difficultiesb 0.027 0.992 0.390 0.010 0.717 0.188
Dependencyb 0.024 0.425 0.544 0.127 0.459 0.927
Drivingc 0.069 0.565 0.518 0.706 0.391 0.906
Color visionb 0.851 0.380 0.114 0.194 0.580 0.704
Peripheral visionb 0.595 0.781 0.658 0.016 0.836 0.352
Total score <0.001 0.188 0.344 0.548 0.834 0.541
Table 5. Analysis of Glaucoma Symptom Scale (GSS) and 25-item National Eye Institute Visual Function 
Questionnaire (NEI-VFQ-25) scores by time, covariates and their interactions (multivariable model). Legend: 
N: Number of participants; BCVA: Best corrected visual acuity (≤0.15 LogMar, >0.15 LogMar); Treat: Number 
of drugs administered (>1 vs 1); aStage = Early (0/borderline/1), Moderate (2/3), Severe (4/5); bDichotomous 
scores (‘ = 100’, ‘<100’); cData available for 111 patients; Bold: Significant values. Model: Score = Baseline score, 
time, Baseline score*time, time*gender, time*age, time*baseline stage, time*BCVA, time*Treat.
Figure 2. Estimated quality of life scores by time and covariates (multivariable analysis). (A) Estimated GSS 
Symp-6 (Symptoms), Func-4 (Function) and Total score variations over time, according to score at baseline; (B) 
Estimated NEI-VFQ-25 General Health, General Vision and Total score variations over time, according to score 
at baseline.
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patients as closely as possible. Third, patients were treated at physician’s discretion during the follow-up, in order 
to delay the progression of the disease. A precise evaluation of QoL and symptoms in surgically-treated patients 
was not feasible, due to the low number of patients that underwent surgery during the follow-up. On the other 
hand, all the patients receiving laser treatment were simultaneously treated with topical medical therapy, so it is 
reasonable to suppose that QoL and symptoms in this group were similar to the rest of the studied population.
In conclusion, this study has demonstrated an increase in vision-related QoL scores and a reduction in 
glaucoma-related symptom perception over one-year follow-up in a population of newly-diagnosed glaucoma 
patients. Although the precise explanation for these findings is uncertain, psychological processes and adaptation 
to the diagnosis of a chronic illness might have played a role. Future research is warranted in order to evaluate 
possible changes of vision-related QoL in a larger sample of glaucoma patients with a more extended follow-up.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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